GeneDx Holdings Corp. splits its revenue 2 ways in its filings. By operating segments, the largest line in fiscal 2025, which ended Dec 31, 2025 was Gene Dx at $423.1 million, 99% of the total. By sales mix, the largest line in fiscal 2025, which ended Dec 31, 2025 was Diagnostic Test Third Party Insurance at $345.2 million, 81% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
454
|
428
|
305
|
203
|
235
|
212
|
| Operating segments | ||||||
| Gene Dx |
—
|
423
+40.0%
share 99.0%
|
302
+55.5%
share 99.0%
|
194
+59.0%
share 96.0%
|
122
share 52.1%
|
—
|
| All Other Segments |
—
|
4
+41.0%
share 1.0%
|
3
-61.5%
share 1.0%
|
8
-92.7%
share 4.0%
|
112
share 47.9%
|
—
|
| Sales mix | ||||||
| Diagnostic Test Third Party Insurance |
376
+30.7%
share 82.7%
|
345
+49.1%
share 80.7%
|
232
+83.4%
share 75.8%
|
126
+73.2%
share 62.3%
|
73
-57.0%
share 31.1%
|
170
share 79.9%
|
| Diagnostic Test Institutional Customers |
65
-4.4%
share 14.3%
|
69
+6.0%
share 16.1%
|
65
+9.4%
share 21.3%
|
59
+46.0%
share 29.4%
|
41
+28.5%
share 17.4%
|
32
share 14.9%
|
| Product And Service Other |
10
+115.2%
share 2.3%
|
11
+230.1%
share 2.5%
|
3
-52.4%
share 1.1%
|
7
-6.1%
share 3.4%
|
7
+3.7%
share 3.1%
|
7
share 3.3%
|
| Diagnostic Test Self Pay |
2
+50.8%
share 0.5%
|
1
-41.9%
share 0.3%
|
2
+37.7%
share 0.8%
|
2
+38.4%
share 0.8%
|
1
-67.7%
share 0.5%
|
4
share 1.8%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Health Services (SIC 8000)
- Listed as
- WGS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Stamford, CT
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1818331
- Former names
- Sema4 Holdings Corp. (until Jan 5, 2023); CM Life Sciences, Inc. (until Jul 21, 2021)
Other Services-Health Services companies
- LifeStance Health Group, Inc. LFST
- Privia Health Group, Inc. PRVA
- Pennant Group, Inc. PNTG
- U S Physical Therapy Inc /NV USPH
- InnovAge Holding Corp. INNV
- Omada Health, Inc. OMDA
- P3 Health Partners Inc. PIII
- Alps Group Inc ALPS
Source: SEC EDGAR filings. This is company-reported data, not investment advice.